Analysts Offer Insights on Healthcare Companies: Applied Genetic Technologies (NASDAQ: AGTC), Epizyme (NASDAQ: EPZM) and Invacare Corp (NYSE: IVC)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Applied Genetic Technologies (NASDAQ: AGTC), Epizyme (NASDAQ: EPZM) and Invacare Corp (NYSE: IVC) with bullish sentiments.

Applied Genetic Technologies (NASDAQ: AGTC)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Applied Genetic Technologies (NASDAQ: AGTC), with a price target of $8. The company’s shares closed yesterday at $4.85.

According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -13.1% and a 34.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Iovance Biotherapeutics Inc, and Mateon Therapeutics Inc.

Applied Genetic Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $8.

See today’s analyst top recommended stocks >>

Epizyme (NASDAQ: EPZM)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Epizyme (NASDAQ: EPZM), with a price target of $25. The company’s shares closed yesterday at $14.20.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.8% and a 49.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.

Currently, the analyst consensus on Epizyme is Strong Buy and the average price target is $24.13, representing a 69.9% upside.

In a report issued on April 24, Jefferies also maintained a Buy rating on the stock with a $27 price target.

Invacare Corp (NYSE: IVC)

KeyBanc analyst Matthew Mishan maintained a Buy rating on Invacare Corp (NYSE: IVC) today and set a price target of $23. The company’s shares closed yesterday at $17.35.

Mishan has an average return of 12.9% when recommending Invacare Corp.

According to TipRanks.com, Mishan is ranked #521 out of 4787 analysts.

Invacare Corp has an analyst consensus of Moderate Buy, with a price target consensus of $23.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts